Gynecologic oncologist Dennis Chi reviews the use of minimally invasive techniques such as laparoscopy for the surgical staging of ovarian cancer.
Gynecologic oncologist Dennis Chi describes a clinical trial evaluating secondary cytoreduction with and without HIPEC for various malignancies.
Co-Director of Robotic Surgery Mario Leitao, Jr., describes the emerging role and clear benefits of the robotic platform for operating on gynecologic cancers.
Gynecologic oncologist Oliver Zivanovic describes the use of heated intraperitoneal chemotherapy to treat ovarian cancer.
We offer a comprehensive, multidisciplinary team approach to screening, counseling, and treating women with ovarian cancer. Improved surgical techniques and refinements in postoperative care are largely responsible for recent improvements in outcomes for women with this malignancy. For staging early cancers that appear to be confined to the ovary, our surgeons are often able to use small-incision minimally invasive surgery via standard laparoscopy or the robotically assisted da Vinci® Surgical System – and have found that these approaches are as effective and accurate as staging during open surgery.
Other reported benefits include decreased postoperative pain, improved cosmetic results, and faster recovery.
Our outcomes after surgery for both advanced and recurrent disease are among the best in the world. Notable as well are recent enhancements in chemotherapy regimens, such as intraperitoneal chemotherapy, and progress in ovarian cancer vaccine trials. The trend toward increasingly individualized care continues with the adaptation of such agents as poly-ADP-ribose polymerase (PARP) inhibitors.